Prescriptions and Power: Why Eli Lilly Is Suing Compounding Pharmacies Over Weight Loss Drugs
In the escalating battle over obesity treatment in the United States, the pharmaceutical industry has found an unexpected foe: local ...
The Protein Paradox: Why Absorption, Not Just Intake, Is the New Frontier in Nutrition
At gyms, cafes, and supermarket aisles, protein is king. We stir it into smoothies, sprinkle it on cereal, and chew ...
Parched by Design: Why You’re Always Thirsty in a Well-Hydrated World
Walk through any office, airport terminal, or yoga studio in the West and you’ll likely find someone gripping a water ...
Microbes & Machines: How Gut Health and Virtual Care Are Reshaping Modern Medicine
In 2007, the Human Microbiome Project began mapping the microbial terrain of the human body. At the time, the idea ...
Power Surge: The Promise and Peril of Mitochondria Transplants
At the microscopic heart of every human cell lies a biological paradox: mitochondria, the tiny energy generators that power life, ...
The Seed Oil Panic: Health Crisis or Misdirected Hysteria?
In the kaleidoscopic world of modern nutrition, villains change often. Once it was saturated fat. Then it was carbs. Now, ...
Science vs. Slogan: The Growing Rift Between RFK Jr. and the Public Health Establishment
On April 15, a coalition of 17 national public health organizations, spearheaded by the American Public Health Advocacy Network (APHAN), ...
The Coming Pharma Tariffs: Decoding Trump’s High-Stakes Bet on Drug Supply Chains
Introduction: The Tariff Test Case No One Is Talking About For all the attention given to tariffs on steel, aluminum, ...
The Silence Clause: NIH Halts Grants to Top Universities Amid Veiled Directives
On a quiet Tuesday afternoon in March, a cryptic internal email circulated through the National Institutes of Health (NIH), addressed ...
Fit for Office: Trump’s Health Report Renews Debate on Presidential Transparency
The White House released a brief but definitive medical report on Sunday morning declaring that former President Donald Trump “exhibits ...
Medical Journals Under Scrutiny: DOJ’s Quiet Inquiry Into Scientific Dissent
In the wake of COVID-19 and the increasing politicization of public health, the U.S. Department of Justice has taken an ...
The Physician on Trial: A Broken System, A Profession Reborn
Bad news travels fast. But good news? That takes time. And when it comes to the federal prosecution of physicians, ...
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more